WO2016119031A8 - Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase - Google Patents
Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase Download PDFInfo
- Publication number
- WO2016119031A8 WO2016119031A8 PCT/BR2016/050010 BR2016050010W WO2016119031A8 WO 2016119031 A8 WO2016119031 A8 WO 2016119031A8 BR 2016050010 W BR2016050010 W BR 2016050010W WO 2016119031 A8 WO2016119031 A8 WO 2016119031A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- synthetising
- inflammation
- pharmaceutical composition
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D227/00—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
A presente invenção descreve um novo composto, seu processo de síntese e os usos deste composto, bem como uma composição farmacêutica contendo o referido composto. Especificamente, a presente invenção revela um composto de acordo com a fórmula (I) : seu processo de síntese e composições compreendendo o referido composto. Adicionalmente, a presente invenção também descreve o uso do composto para fabricação de uma composição para o tratamento curativo ou profilático de doenças neurodegenerativas, de inflamações, além de composições anticolinesterásicas. Ainda, a presente invenção descreve métodos de tratamento envolvendo a administração do referido composto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102015002132-1A BR102015002132B1 (pt) | 2015-01-29 | Composto para o tratamento de inflamações e doenças neurodegenerativas, seu processo de preparação, composição, forma de dosagem e uso | |
BR102015002132-1 | 2015-01-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016119031A1 WO2016119031A1 (pt) | 2016-08-04 |
WO2016119031A8 true WO2016119031A8 (pt) | 2016-09-22 |
Family
ID=56542061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2016/050010 WO2016119031A1 (pt) | 2015-01-29 | 2016-01-22 | Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016119031A1 (pt) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5606054A (en) * | 1993-12-14 | 1997-02-25 | Merck & Co., Inc. | Heterocyclic-fused lactams promote release of growth hormone |
EP1512396A4 (en) * | 2002-06-05 | 2008-12-31 | Inst Med Molecular Design Inc | INHIBITORS OF AP-1 AND NFAT ACTIVATION |
JPWO2005007151A1 (ja) * | 2003-07-16 | 2006-08-31 | 株式会社医薬分子設計研究所 | 皮膚色素沈着の治療剤 |
SG10201710543PA (en) * | 2013-06-19 | 2018-02-27 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
-
2016
- 2016-01-22 WO PCT/BR2016/050010 patent/WO2016119031A1/pt active Application Filing
Also Published As
Publication number | Publication date |
---|---|
BR102015002132A2 (pt) | 2016-08-02 |
WO2016119031A1 (pt) | 2016-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017053868A8 (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
NZ724250A (en) | Human plasma kallikrein inhibitors | |
UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
NZ726366A (en) | Syk inhibitors | |
MX2016003582A (es) | Compuesto inhibidor de las actividades de las cinasas btk y/o jak3. | |
MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
PH12020550341A1 (en) | Niraparib formulations | |
MX2008013212A (es) | 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r. | |
TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
PH12015502365B1 (en) | Bace1 inhibitors | |
WO2018111315A8 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES | |
WO2015104292A3 (en) | Compounds for use in treating or preventing cancerous diseases | |
EA201171088A1 (ru) | Лечение дискинезии при различных расстройствах | |
PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
WO2013188268A8 (en) | Topical ophthalmological pharmaceutical composition containing pazopanib | |
SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
MX2009007889A (es) | Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer. | |
WO2017053711A3 (en) | Deuterated cftr potentiators | |
PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
PH12017501668A1 (en) | Bace1 inhibitors | |
MX2018002177A (es) | Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16742595 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16742595 Country of ref document: EP Kind code of ref document: A1 |